Cns Pharmaceuticals 

€0,5900
88
-€0,08-11,94% Monday 06:06

İstatistikler

Günün en yüksek
0,65
Günlük en düşük
0,65
52H Zirve
-
52H Dip
-
Hacim
-
Ort. Hacim
-
Piyasa değeri
0
F/K Oranı
-
Temettü verimi
-
Temettü
-

Finansal sonuçlar

18AugBeklenen
Q3 2024
Q1 2025
Q2 2025
-21,45
-15,88
-10,31
-4,75
Beklenen EPS
-8.40288
Gerçekleşen EPS
Yok

Finansallar

-Kâr marjı
Kârsız
2019
2020
2021
2022
2023
2024
0Gelir
-2,48MNet kâr

Rakipler

Bu liste, son piyasa olaylarına dayalı bir analizdir. Yatırım tavsiyesi değildir.
Alkermes
ALKS
Piyasa değeri7,95B
Alkermes plc, merkezi sinir sistemi (CNS) hastalıkları üzerinde çalışarak, CNSP'nin ürün yelpazesiyle doğrudan rekabet edebilecek ürünler sunmaktadır.
Biogen
BIIB
Piyasa değeri32,28B
Biogen Inc., nörolojik ve nörodejeneratif hastalıklar için geniş bir tedavi portföyüne sahip olup, CNS alanında rekabet etmektedir.
Acadia Pharmaceuticals
ACAD
Piyasa değeri5,02B
ACADIA Pharmaceuticals, merkezi sinir sistemi bozukluklarını tedavi etmek için ilaçların geliştirilmesi ve pazarlanmasına odaklanırken, CNSP ile doğrudan rekabet ediyor.
AMGEN
AMGN
Piyasa değeri233,78B
Amgen Inc., nörolojik bozukluklar için tedaviler de dahil olmak üzere çeşitli biyofarmasötik portföye sahip olup CNS pazarında bir rakip haline gelmektedir.
Novartis
NVS
Piyasa değeri292,35B
Novartis AG, CNS bozuklukları için tedaviler de dahil olmak üzere geniş bir sağlık çözümleri yelpazesi sunmaktadır ve CNSP'nin terapötik alanlarıyla rekabet etmektedir.
Pfizer
PFE
Piyasa değeri159,36B
Pfizer Inc., nörolojik koşullar için ilaç geliştirme konusunda önemli bir varlığa sahip olup, CNS ilaçları pazarında bir rakip haline gelmektedir.
Merck
MRK
Piyasa değeri366B
Merck & Co., Inc., CNS bozuklukları da dahil olmak üzere çeşitli hastalıklar için tedaviler geliştirerek CNSP'ye rakip olmaktadır.
Johnson & Johnson
JNJ
Piyasa değeri645,95B
Johnson & Johnson, ilaç bölümü Janssen aracılığıyla merkezi sinir sistemi bozuklukları için tedaviler geliştirirken, genel sağlık pazarında CNSP ile rekabet ediyor.

Hakkında

Monumental Minerals Corp., an exploration stage company, engages in the acquisition and exploration of mineral properties in Canada and Mexico, and Chile. It has an option to acquire 100% interest in the Jemi Project consisting of 6 mineral concessions comprising approximately 3,560 hectares located in the Ocampo municipality of Coahuila State, Mexico; a 75% interest in the Laguna Project that covers 5200-hectares located near the town of San Pedro de Atacama, Chile; and a 50.01% interest in the Turi project located within the Lithium triangle northeast from the city of Calama, Chile. The company was formerly known as Monumental Gold Corp. and changed its name to Monumental Minerals Corp. in November 2021. Monumental Minerals Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.
Show more...
CEO
Ülke
Almanya
ISIN
US18978H4092
WKN
000A41140

Kotasyonlar

0 Comments

Düşüncelerini paylaş

FAQ

Cns Pharmaceuticals hissesinin bugünkü fiyatı nedir?
BE5.F’un güncel fiyatı €0,59 EUR — son 24 saatte %-11,94% düştü. Cns Pharmaceuticals hissesinin fiyat performansını grafikte daha yakından izle.
Cns Pharmaceuticals hissesinin sembolü nedir?
Borsaya bağlı olarak hisse sembolü değişebilir. Örneğin, Frankfurt Exchange borsasında Cns Pharmaceuticals hisseleri BE5.F sembolüyle işlem görür.
Cns Pharmaceuticals’in geçen yılki geliri ne kadardı?
Cns Pharmaceuticals’in geçen yılki geliri 0 EUR tutarındadır.
Cns Pharmaceuticals’in geçen yılki net geliri neydi?
BE5.F’in geçen yılki net geliri -2,48M EUR.
Cns Pharmaceuticals hangi sektörde yer alıyor?
Cns Pharmaceuticals, Materyaller sektöründe faaliyet göstermektedir.
Cns Pharmaceuticals hisse bölünmesini ne zaman tamamladı?
Cns Pharmaceuticals son zamanlarda herhangi bir split gerçekleştirmedi.
dan işlem görüyor.","summary":"","url":"https://247wallst.com/investing/2026/05/14/forget-the-242-biotech-meme-this-brain-cancer-stock-has-a-38-analyst-target-and-trades-at-6/","imageUrl":"https://assets.stockevents.app/images/xl/ad1dad9a-1dc5-4fc6-b893-9af1e4393d7a.webp","sentiment":"","type":"Article","sourceName":"24/7 Wall St.","topics":[]},{"id":61486140,"symbols":["CELC","CNSP","GBTG"],"date":"2026-05-04T17:59:16Z","title":"Top Midday Gainers","summary":"","url":"https://finance.yahoo.com/markets/stocks/articles/top-midday-gainers-175916330.html","imageUrl":"","sentiment":"","type":"Article","sourceName":"MT Newswires","topics":[]},{"id":61417228,"symbols":["88E.AU","AUNXF","AXP.AU","AZRH","BWEFF","BWERY","CCEC","CCEYF","DPLS","EEENF","KGEI","MNMRF","OMV.VI","OMVJF","OMVKY","SEI","SEUSF","SYNTF","VLERF"],"date":"2026-04-09T12:00:00Z","title":"Oil & Gas Companies to Present at Virtual Investor Conference on April 16th","summary":"","url":"https://finance.yahoo.com/sectors/energy/articles/oil-gas-companies-present-virtual-120000301.html","imageUrl":"https://assets.stockevents.app/images/xl/b09a2d0b-3207-4850-afea-b105b414a188.webp","sentiment":"","type":"Article","sourceName":"GlobeNewswire","topics":[]},{"id":61374351,"symbols":["MNRG.V"],"date":"2026-03-30T12:51:19Z","title":"Monumental Energy Reports Initial Flush Production of 3000 Barrels and Stable Unstimulated Flow Rate of 300 Barrels a Day at Ngaere-2","summary":"","url":"https://finance.yahoo.com/sectors/energy/articles/monumental-energy-reports-initial-flush-125119091.html","imageUrl":"","sentiment":"","type":"Article","sourceName":"MT Newswires","topics":[]},{"id":61373639,"symbols":["MNMRF","MNRG.V"],"date":"2026-03-30T11:00:00Z","title":"Monumental Energy Reports Initial Flush Production of 3000 Barrels and a Stable Unstimulated Flow Rate of 300 Barrels a Day at Ngaere-2","summary":"","url":"https://finance.yahoo.com/sectors/energy/articles/monumental-energy-reports-initial-flush-110000587.html","imageUrl":"","sentiment":"","type":"Article","sourceName":"Business Wire","topics":[]},{"id":61333621,"symbols":["MNRG.V","NZ.V","NZERF"],"date":"2026-03-19T12:30:00Z","title":"New Zealand Energy Corp. Announces Successful Production from Waihapa H1 Well","summary":"","url":"https://finance.yahoo.com/sectors/energy/articles/zealand-energy-corp-announces-successful-123000147.html","imageUrl":"https://assets.stockevents.app/images/xl/ecd6faa6-73a7-436f-8609-c3fbf9cc43bb.webp","sentiment":"","type":"Article","sourceName":"TMX Newsfile","topics":[]},{"id":61332983,"symbols":["MNMRF","MNRG.V","NZ.V"],"date":"2026-03-19T11:00:00Z","title":"Monumental Energy Reports Initial Flush Production of 3,000 Barrels and a Stable Unstimulated Flow Rate of 568 Barrels Per Day From Waihapa H1","summary":"","url":"https://finance.yahoo.com/sectors/energy/articles/monumental-energy-reports-initial-flush-110000839.html","imageUrl":"","sentiment":"","type":"Article","sourceName":"Business Wire","topics":[]},{"id":61316325,"symbols":["MNMRF","MNRG.V","NZ.V","ZA6.F"],"date":"2026-03-16T11:00:00Z","title":"Monumental Energy Announces Commercial Production at Waihapa H1","summary":"","url":"https://finance.yahoo.com/news/monumental-energy-announces-commercial-production-110000937.html","imageUrl":"","sentiment":"","type":"Article","sourceName":"Business Wire","topics":[]},{"id":61315978,"symbols":["MNMRF","MNRG.V","NZ.V","ZA6.F"],"date":"2026-03-16T10:31:00Z","title":"MONUMENTAL ENERGY ANNOUNCES COMMERCIAL PRODUCTION AT WAIHAPA H1","summary":"","url":"https://finance.yahoo.com/news/monumental-energy-announces-commercial-production-103100895.html","imageUrl":"https://assets.stockevents.app/images/xl/a6730089-9a87-46e6-a649-95df50010cdd.webp","sentiment":"","type":"Article","sourceName":"GlobeNewswire","topics":[]},{"id":61297835,"symbols":["CNSP"],"date":"2026-03-11T12:35:00Z","title":"CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-launches-corporate-strategy-123500247.html","imageUrl":"https://assets.stockevents.app/images/xl/1e6980ab-0a5a-4d35-869c-27ee0ef2d29b.webp","sentiment":"","type":"Article","sourceName":"ACCESS Newswire","topics":[]},{"id":61291128,"symbols":["MNMRF","MNRG.V","NZ.V","ZA6.F"],"date":"2026-03-10T11:00:00Z","title":"Monumental Energy Announces Perforations Have Commenced at the Waihapa H1 Well","summary":"","url":"https://finance.yahoo.com/news/monumental-energy-announces-perforations-commenced-110000765.html","imageUrl":"","sentiment":"","type":"Article","sourceName":"Business Wire","topics":[]},{"id":61286041,"symbols":["MNRG.V","NZ.V","NZERF"],"date":"2026-03-09T12:30:00Z","title":"New Zealand Energy Corp. Provides Operational Update","summary":"","url":"https://finance.yahoo.com/news/zealand-energy-corp-provides-operational-123000102.html","imageUrl":"https://assets.stockevents.app/images/xl/66905d5b-c906-4e19-8190-0ea3e951f1b6.webp","sentiment":"","type":"Article","sourceName":"TMX Newsfile","topics":[]},{"id":61254645,"symbols":["CNSP"],"date":"2026-03-02T13:25:00Z","title":"CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-appoints-lynne-kelley-132500757.html","imageUrl":"https://assets.stockevents.app/images/xl/1045fd27-6965-4f09-81a2-bc9f7932221e.webp","sentiment":"","type":"Article","sourceName":"ACCESS Newswire","topics":[]},{"id":61194410,"symbols":["CNSP"],"date":"2026-02-17T13:25:00Z","title":"CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-appoints-multiple-key-132500001.html","imageUrl":"https://assets.stockevents.app/images/xl/a96c823e-5617-459a-892b-e829a278926f.webp","sentiment":"","type":"Article","sourceName":"ACCESS Newswire","topics":[]},{"id":61136464,"symbols":["MNMRF","NZERF"],"date":"2026-02-04T13:30:00Z","title":"New Zealand Energy Corp. Closes Funding Agreement","summary":"","url":"https://finance.yahoo.com/news/zealand-energy-corp-closes-funding-133000726.html","imageUrl":"https://assets.stockevents.app/images/xl/f64fa27f-3d9a-4e9f-a0f0-8cf311e49d90.webp","sentiment":"","type":"Article","sourceName":"TMX Newsfile","topics":[]},{"id":61096943,"symbols":["CNSP"],"date":"2026-01-27T14:00:00Z","title":"CNS Pharmaceuticals Issues Letter to Shareholders","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-issues-letter-shareholders-140000389.html","imageUrl":"https://assets.stockevents.app/images/xl/bc693b10-0264-492c-b079-218abacf2201.webp","sentiment":"","type":"Article","sourceName":"ACCESS Newswire","topics":[]},{"id":61032009,"symbols":["MNMRF","NZERF"],"date":"2026-01-13T13:30:00Z","title":"New Zealand Energy Corp. Enters into Funding Agreement to Increase Production at Waihapa-Ngaere","summary":"","url":"https://finance.yahoo.com/news/zealand-energy-corp-enters-funding-133000871.html","imageUrl":"https://assets.stockevents.app/images/xl/bbcafe89-e6d4-4036-8bc2-10c29a5644f8.webp","sentiment":"","type":"Article","sourceName":"TMX Newsfile","topics":[]},{"id":60941558,"symbols":["CNSP"],"date":"2025-12-17T12:00:00Z","title":"CNS Pharmaceuticals Announces CEO Transition","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-ceo-transition-120000083.html","imageUrl":"https://assets.stockevents.app/images/xl/aaa32522-75ac-4cc9-a0e9-0d797b6f697e.webp","sentiment":"","type":"Article","sourceName":"ACCESS Newswire","topics":["ceo"]},{"id":60809662,"symbols":["CNSP"],"date":"2025-11-17T13:35:00Z","title":"CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-third-quarter-133500002.html","imageUrl":"https://assets.stockevents.app/images/xl/f323aa27-8181-4b22-8a2c-7ce4ba9c5717.webp","sentiment":"","type":"Article","sourceName":"ACCESS Newswire","topics":[]},{"id":60772949,"symbols":["CNSP"],"date":"2025-11-10T13:45:00Z","title":"CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-acceptance-three-134500171.html","imageUrl":"https://assets.stockevents.app/images/xl/f6d9aa4e-6b86-489c-887e-ddebd6338239.webp","sentiment":"","type":"Article","sourceName":"ACCESS Newswire","topics":[]},{"id":60712024,"symbols":["MNMRF","MNRG.V"],"date":"2025-10-30T12:00:00Z","title":"Monumental Energy Announces Private Placement Financing","summary":"","url":"https://finance.yahoo.com/news/monumental-energy-announces-private-placement-120000267.html","imageUrl":"","sentiment":"","type":"Article","sourceName":"Business Wire","topics":[]},{"id":60486769,"symbols":["CNSP"],"date":"2025-09-13T13:05:32Z","title":"CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap","summary":"","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-upgraded-buy-maxim-130532100.html","imageUrl":"https://assets.stockevents.app/images/xl/5c7823b0-e4b3-4ad6-a745-712c5a9c26f9.webp","sentiment":"","type":"Article","sourceName":"TipRanks","topics":[]}]},"requestCountry":""}; window.anonymousUserId = 'be640db0-bece-11ea-dbe5-7da5f4bf85d3'; window.refreshToken = 'eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJleHAiOjQ5NDIwOTgwNjQsInJlZnJlc2hfdXVpZCI6ImE5NTkyZDk3LWYyZDAtNDMwNy1iZWRlLWVlNjgzMDE0NzU2NCsrYmU2NDBkYjAtYmVjZS0xMWVhLWRiZTUtN2RhNWY0YmY4NWQzIiwidXNlcl9pZCI6ImJlNjQwZGIwLWJlY2UtMTFlYS1kYmU1LTdkYTVmNGJmODVkMyJ9.9TiB62ur5t3pMeD09N-X78ytjxU1o7W7U-lDztSUu24'; window.accessToken = 'eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJhY2Nlc3NfdXVpZCI6ImE5NTkyZDk3LWYyZDAtNDMwNy1iZWRlLWVlNjgzMDE0NzU2NCIsImF1dGhvcml6ZWQiOnRydWUsImV4cCI6MTc4ODUwMTY2NCwidXNlcl9pZCI6ImJlNjQwZGIwLWJlY2UtMTFlYS1kYmU1LTdkYTVmNGJmODVkMyJ9.DAWc7nV88P95PLgXVBg1Jan1ziYiHXwf0U-s58_JZzs'; window.isBot = true; window.apiUrl = '/api/'; window.cloudflareTurnstileSiteKey = "0x4AAAAAADNJpCHEAHWMSwjy"; window.abVariants = {"home":"v6","dividends":"v4"}; window.staticData = {"homeHeroVideo":null};

Cns Pharmaceuticals 

€0,5900
88
-€0,08-11,94% Monday 06:06

İstatistikler

Günün en yüksek
0,65
Günlük en düşük
0,65
52H Zirve
-
52H Dip
-
Hacim
-
Ort. Hacim
-
Piyasa değeri
0
F/K Oranı
-
Temettü verimi
-
Temettü
-

Finansal sonuçlar

18AugBeklenen
Q3 2024
Q1 2025
Q2 2025
-21,45
-15,88
-10,31
-4,75
Beklenen EPS
-8.40288
Gerçekleşen EPS
Yok

Finansallar

-Kâr marjı
Kârsız
2019
2020
2021
2022
2023
2024
0Gelir
-2,48MNet kâr

Rakipler

Bu liste, son piyasa olaylarına dayalı bir analizdir. Yatırım tavsiyesi değildir.
Alkermes
ALKS
Piyasa değeri7,95B
Alkermes plc, merkezi sinir sistemi (CNS) hastalıkları üzerinde çalışarak, CNSP'nin ürün yelpazesiyle doğrudan rekabet edebilecek ürünler sunmaktadır.
Biogen
BIIB
Piyasa değeri32,28B
Biogen Inc., nörolojik ve nörodejeneratif hastalıklar için geniş bir tedavi portföyüne sahip olup, CNS alanında rekabet etmektedir.
Acadia Pharmaceuticals
ACAD
Piyasa değeri5,02B
ACADIA Pharmaceuticals, merkezi sinir sistemi bozukluklarını tedavi etmek için ilaçların geliştirilmesi ve pazarlanmasına odaklanırken, CNSP ile doğrudan rekabet ediyor.
AMGEN
AMGN
Piyasa değeri233,78B
Amgen Inc., nörolojik bozukluklar için tedaviler de dahil olmak üzere çeşitli biyofarmasötik portföye sahip olup CNS pazarında bir rakip haline gelmektedir.
Novartis
NVS
Piyasa değeri292,35B
Novartis AG, CNS bozuklukları için tedaviler de dahil olmak üzere geniş bir sağlık çözümleri yelpazesi sunmaktadır ve CNSP'nin terapötik alanlarıyla rekabet etmektedir.
Pfizer
PFE
Piyasa değeri159,36B
Pfizer Inc., nörolojik koşullar için ilaç geliştirme konusunda önemli bir varlığa sahip olup, CNS ilaçları pazarında bir rakip haline gelmektedir.
Merck
MRK
Piyasa değeri366B
Merck & Co., Inc., CNS bozuklukları da dahil olmak üzere çeşitli hastalıklar için tedaviler geliştirerek CNSP'ye rakip olmaktadır.
Johnson & Johnson
JNJ
Piyasa değeri645,95B
Johnson & Johnson, ilaç bölümü Janssen aracılığıyla merkezi sinir sistemi bozuklukları için tedaviler geliştirirken, genel sağlık pazarında CNSP ile rekabet ediyor.

Hakkında

Monumental Minerals Corp., an exploration stage company, engages in the acquisition and exploration of mineral properties in Canada and Mexico, and Chile. It has an option to acquire 100% interest in the Jemi Project consisting of 6 mineral concessions comprising approximately 3,560 hectares located in the Ocampo municipality of Coahuila State, Mexico; a 75% interest in the Laguna Project that covers 5200-hectares located near the town of San Pedro de Atacama, Chile; and a 50.01% interest in the Turi project located within the Lithium triangle northeast from the city of Calama, Chile. The company was formerly known as Monumental Gold Corp. and changed its name to Monumental Minerals Corp. in November 2021. Monumental Minerals Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.
Show more...
CEO
Ülke
Almanya
ISIN
US18978H4092
WKN
000A41140

Kotasyonlar

0 Comments

Düşüncelerini paylaş

FAQ

Cns Pharmaceuticals hissesinin bugünkü fiyatı nedir?
BE5.F’un güncel fiyatı €0,59 EUR — son 24 saatte %-11,94% düştü. Cns Pharmaceuticals hissesinin fiyat performansını grafikte daha yakından izle.
Cns Pharmaceuticals hissesinin sembolü nedir?
Borsaya bağlı olarak hisse sembolü değişebilir. Örneğin, Frankfurt Exchange borsasında Cns Pharmaceuticals hisseleri BE5.F sembolüyle işlem görür.
Cns Pharmaceuticals’in geçen yılki geliri ne kadardı?
Cns Pharmaceuticals’in geçen yılki geliri 0 EUR tutarındadır.
Cns Pharmaceuticals’in geçen yılki net geliri neydi?
BE5.F’in geçen yılki net geliri -2,48M EUR.
Cns Pharmaceuticals hangi sektörde yer alıyor?
Cns Pharmaceuticals, Materyaller sektöründe faaliyet göstermektedir.
Cns Pharmaceuticals hisse bölünmesini ne zaman tamamladı?
Cns Pharmaceuticals son zamanlarda herhangi bir split gerçekleştirmedi.